![](https://www.karyopharm.com/wp-content/uploads/2020/12/Going-Nuclear2_website-banner-1920x600.jpg)
Going Nuclear 2: The Role of XPO1 in Diffuse Large B-cell Lymphoma
Join lymphoma experts Dr. Peter Martin, Dr. Erlene Seymour, and Dr. Tom Witzig for a discussion of recent advances in patient care. You will learn how inhibiting a key protein, XPO1, is impacting the current treatment paradigm.
Friday, January 22, 2021
1-2 PM (EST)
![](https://www.karyopharm.com/wp-content/uploads/2020/12/PeterMartinMD_circle.png)
Weil Cornell Medicine
![](https://www.karyopharm.com/wp-content/uploads/2020/12/ErleneSmourMD_circle.png)
Karmanos Cancer Institute
![](https://www.karyopharm.com/wp-content/uploads/2020/12/TomWitzigMD_circle.png)
Mayo Clinic